Chronic hepatitis; Cirrhosis; Hepatitis C; Hepatocellular carcinoma
Terziroli Beretta-Piccoli Benedetta, Di Bartolomeo Claudia, Deleonardi Gaia, Grondona Ana Gabriela, Silvestri Tania, Tesei Cinzia, Melidona Laura, Cerny Andreas, Mertens Joachim, Semmo Nasser, Semela David, Moradpour Darius, Mieli-Vergani Giorgina, Vergani Diego, Muratori Luigi (2019), Autoimmune liver serology before and after successful treatment of chronic hepatitis C by direct acting antiviral agents, in Journal of Autoimmunity
, 102, 89-95.
Brezzi Matteo, Bertisch Barbara, Roelens Maroussia, Moradpour Darius, Terziroli Beretta-Piccoli Benedetta, Semmo Nasser, Müllhaupt Beat, Semela David, Negro Francesco, Keiser Olivia (2019), Impact of geographic origin on access to therapy and therapy outcomes in the Swiss Hepatitis C Cohort Study, in PLOS ONE
, 14(6), e0218706-e0218706.
Bertisch Barbara, Brezzi Matteo, Negro Francesco, Müllhaupt Beat, Ottiger Cornelia, Künzler-Heule Patrizia, Schmid Patrick, Giudici Fabio, Clerc Olivier, Moriggia Alberto, Roelens Maroussia, Marinucci Francesco, Zehnder Cinzia, Moradpour Darius, Keiser Olivia, Negro Francesco, Kaiser Laurent, Heim Markus, Hirsch Hans, Dufour Jean-François, Semmo Nasser, Moradpour Darius, Aubert Vincent, Siegrist Hans H, et al. (2019), Very Low Hepatitis C Viral Loads in Treatment-naive Persons: Do They Compromise Hepatitis C Virus Antigen Testing?, in Clinical Infectious Diseases
Keiser O., Giudici F., Müllhaupt B., Junker C., Dufour J. -F., Moradpour D., Bruggmann P., Terziroli B., Semela D., Brezzi M., Bertisch B., Estill J., Negro F., Spoerri A. (2018), Trends in hepatitis C-related mortality in Switzerland, in Journal of Viral Hepatitis
, 25(2), 152-160.
About Frédégonde, BibertStéphanie, JuanguyEmmanuelle, NalpasBertrand, LorenzoLazaro, RattinaVimel, ZarhrateMohammed, HaneinSylvain, MunteanuMona, MüllhauptBeat, SemelaDavid, SemmoNasser, CasanovaJean-Laurent, TheodorouIoannis, SultanikPhilippe, PoynardThierry, PolStanislas, BochudPierre-Yves, CobatAurélie, Aebl Laurent, Identification of an endoglin variant associated with HCV-related liver fibrosis pro-gression by next-generation sequencing, in Front Genet
, 10, 1024.
The hepatitis C virus (HCV) is a major human pathogen, affecting approximately 71 million persons globally, and ~60,000 in Switzerland. Hepatitis C is an important cause of liver- and non-liver-related morbidity and mortality. Hepatitis C is not only the first indication to liver transplant in most Western countries, but, even in the precirrhotic stage, it also exerts a significant decrease in quality-of-life in a large proportion of patients. Incidence and prevalence data suggest that impressive increases in advanced liver diseases states and complications in Switzerland will occur during the next 10 years, translating into a dramatic increase in HCV-related health care costs. Available therapies are safe end effective, allow curing HCV infection in >95% of patients. However, barriers to therapy are and will remain significant, due to ineffective screening strategies, insufficient retention in care, and high costs. In addition, morbidity after cure may remain significant, especially as far as hepatocellular carcinoma recurrence is concerned. Thus, HCV infection impacts heavily today and will continue to impact in the mid-term future on patients' quality of life and health care resources. Large population-based studies have been proven to be the most meaningful approach to verify working hypotheses on clinical and pathogenetic issues regarding HCV infection. The Swiss Hepatitis C Cohort Study (SCCS) was founded in 2000 by representatives of the 8 major HCV tertiary referral centers across Switzerland. The SCCS has continued to recruit patients during the past 12 years, despite severe budgetary restrictions, and can count today on >5,200 anti-HCV+ enrolled patients, representative of the general HCV-infected population. Data and samples collected within the framework of the SCCS have helped accomplishing several seminal scientific projects, including the pioneering characterization of the clinical significance of IFNL3 gene polymorphisms. In the next years, the SCCS will provide a very powerful framework for generating additional information on the pathogenesis and natural history of HCV infection, and for contributing efficacy and safety data of novel antiviral therapies.